Provided by Tiger Trade Technology Pte. Ltd.

Cogent

8.46
+0.23002.79%
Post-market: 8.460.00000.00%19:30 EDT
Volume:2.48M
Turnover:20.89M
Market Cap:433.29M
PE:-8.98
High:8.59
Open:8.37
Low:8.12
Close:8.23
52wk High:45.69
52wk Low:7.13
Shares:51.22M
Float Shares:45.32M
Volume Ratio:1.23
T/O Rate:5.47%
Dividend:0.08
Dividend Rate:0.95%
EPS(TTM):-0.9421
EPS(LYR):-3.8009
ROE:-721.50%
ROA:-1.24%
PB:-12.70
PE(LYR):-2.23

Loading ...

Cogent Comms Hldgs Q1 EPS $(0.83) Beats $(0.95) Estimate, Sales $239.187M Miss $241.924M Estimate

Benzinga Earnings
·
May 04

Cogent Q1 FY26 net loss widens to $39.5 million; revenue falls 3.2% to $239.2 million

Reuters
·
May 04

BRIEF-Cogent Communications Q1 Basic EPS USD -0.83 Vs. IBES Estimate USD -1

Reuters
·
May 04

Cogent Communications Q1 Adjusted Gross Margin 46.1%

THOMSON REUTERS
·
May 04

Cogent Communications Q1 Ebitda USD 45.183 Million

THOMSON REUTERS
·
May 04

Cogent Communications Q1 Adjusted Ebitda USD 70.183 Million VS. Ibes Estimate USD 73.5 Million

THOMSON REUTERS
·
May 04

Cogent Communications Reports First Quarter 2026 Results

THOMSON REUTERS
·
May 04

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 04

Cogent Communications Holdings Inc expected to post a loss of 100 cents a share - Earnings Preview

Reuters
·
May 01

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 01

Earning Preview: Cogent Communications Holdings, Inc. revenue is expected to decrease by 3.60%, and institutional views are cautious

Earnings Agent
·
Apr 27

Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire
·
Apr 21

A Look At Cogent Communications Holdings’s Valuation After Its Recent Share Price Rebound

Simply Wall St.
·
Apr 20

Cogent Communications Weighs Liquidity Risks Against Valuation Discount

Simply Wall St.
·
Apr 19

Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

GlobeNewswire
·
Apr 17

Cogent to host first-quarter earnings call May 4

Reuters
·
Apr 15

Cogent Communications to See 'Soft' Q1, 'Strong Rebound' in H2, Oppenheimer Says

MT Newswires Live
·
Apr 08

Cogent Biosciences submits bezuclastinib new drug application to the FDA

TIPRANKS
·
Apr 01

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

GlobeNewswire
·
Apr 01

Cogent Biosciences Advances CGT6297 Into First-in-Human Trial for PIK3CA-Driven Cancers

TIPRANKS
·
Mar 28